You are here

ONEVAX, LLC

Company Information
Address 1928 SW 36TH PL
GAINESVILLE, FL, 32608-3436


Information

DUNS: 004095863

# of Employees: 3


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Development of a dual microparticle platform vaccine system encapsulating immunomodulatory agents and antigen for the amelioration of type 1 diabetes

    Amount: $221,331.00

    Immune mediated diseases such as typediabetesT Dmultiple sclerosisrheumatoid arthritisand systemic lupus erythematosis are reaching epidemic proportions in the UST D results from abreakdown of self to ...

    SBIRPhase I2018Department of Health and Human Services
  2. Biomaterial-Based Delivery of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type 1 Diabetes

    Amount: $195,808.00

    TypeDiabetesT Dresults from a breakdown of self tolerance that is characterized by immune cell mediated destruction of the insulin producingcells in the pancreasUltimatelyglucose metabolism is interru ...

    SBIRPhase I2018Department of Health and Human Services
  3. A novel biomaterial based therapy utilizing auto antigen and adjuvant for the amelioration of Type Diabetes

    Amount: $238,328.00

    Immune mediated diseases such as type diabetes T D multiple sclerosis rheumatoid arthritis and systemic lupus erythematosis are reaching epidemic proportions in the US T D affects an estimated ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  4. Biomaterial based delivery of Interleukin to Regulatory T Cells for the amelioration of Type Diabetes

    Amount: $235,720.00

    Type Diabetes T D results from a breakdown of self tolerance that is characterized by immune cell mediated destruction of the insulin producing cells in the pancreas Ultimately glucose metabol ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  5. Therapeutic Administration of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type Diabetes

    Amount: $117,817.00

    Type Diabetes T D results from a breakdown of self tolerance that is characterized by immune cell mediated destruction of the insulin producing cells in the pancreas Ultimately glucose metabol ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
  6. A novel biomaterial-based therapy to prevent type 1 diabetes

    Amount: $200,212.00

    DESCRIPTION (provided by applicant): Immune-mediated diseases such as type 1 diabetes (T1D), multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosis are reaching epidemic proportion ...

    SBIRPhase I2014Department of Health and Human Services
  7. Fast and Accurate Dynamic Simulations of Biological Systems

    Amount: $226,205.00

    DESCRIPTION (provided by applicant): Type 1 Diabetes (T1D) is thought to result from a breakdown of self-tolerance that is characterized by T cell-mediated destruction of the insulin-producing -cells ...

    SBIRPhase I2013Department of Health and Human Services
US Flag An Official Website of the United States Government